Bank of New York Mellon
GLUE icon

Bank of New York Mellon’s Monte Rosa Therapeutics GLUE Stock Holding History

Bank of New York Mellon’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.39M Buy
222,521
+17,834
+9% +$337K ﹤0.01% 2399
2026
Q1 		$3.37M Buy
204,687
+31,383
+18% +$600K ﹤0.01% 2529
2025
Q4 		$2.72M Sell
173,304
-13,494
-7% -$182K ﹤0.01% 2666
2025
Q3 		$1.38M Buy
186,798
+11,455
+7% +$60.7K ﹤0.01% 3019
2025
Q2 		$791K Buy
175,343
+11,198
+7% +$49.9K ﹤0.01% 3248
2025
Q1 		$762K Sell
164,145
-6,167
-4% -$37.8K ﹤0.01% 3207
2024
Q4 		$1.18M Buy
170,312
+3,619
+2% +$27.2K ﹤0.01% 3050
2024
Q3 		$883K Buy
166,693
+56,829
+52% +$287K ﹤0.01% 3210
2024
Q2 		$411K Buy
109,864
+15,845
+17% +$80.8K ﹤0.01% 3684
2024
Q1 		$663K Sell
94,019
-6,497
-6% -$38.5K ﹤0.01% 3360
2023
Q4 		$568K Buy
100,516
+6,461
+7% +$25.3K ﹤0.01% 3482
2023
Q3 		$451K Sell
94,055
-35
-0% -$225 ﹤0.01% 3603
2023
Q2 		$645K Buy
94,090
+5,635
+6% +$36.4K ﹤0.01% 3456
2023
Q1 		$689K Sell
88,455
-837
-0.9% -$5.82K ﹤0.01% 3319
2022
Q4 		$680K Buy
89,292
+1,660
+2% +$13.8K ﹤0.01% 3388
2022
Q3 		$716K Buy
87,632
+17,424
+25% +$160K ﹤0.01% 3373
2022
Q2 		$679K Sell
70,208
-4,111
-6% -$41.3K ﹤0.01% 3413
2022
Q1 		$1.04M Buy
74,319
+42,340
+132% +$588K ﹤0.01% 3287
2021
Q4 		$653K Buy
31,979
+4,123
+15% +$86.3K ﹤0.01% 3632
2021
Q3 		$621K Buy
+27,856
New +$798K ﹤0.01% 3674

Other funds holding GLUE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Bank of New York Mellon's GLUE Position: Q2 2026 in Review

Bank of New York Mellon increased its Monte Rosa Therapeutics (GLUE) stake by 8.7% in Q2 2026, buying an estimated $337K and bringing the position to 222,521 shares worth $5.39M. The position accounts for ﹤0.01% of the portfolio, ranked #2399.

Bank of New York Mellon first reported a position in GLUE in Q3 2021 and has held it in 20 quarters since. 58 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Bank of New York Mellon held 222,521 shares of Monte Rosa Therapeutics worth $5.39M as of Q2 2026.
  • Bank of New York Mellon bought 17,834 Monte Rosa Therapeutics shares in Q2 2026, an estimated $337K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2399 holding.
  • Bank of New York Mellon first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • 58 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.